The hydroxymethylglutaryl-coenzyme A reductase inhibitors (HMG-CoAs) are one of the most significant causes of medication induced rhabdomyolysis. The development of rhabdomyolysis is increased when the HMG-CoAs are used concurrently with certain other medications, specifically gemfibrozil and macrolide antibiotics. In this report, we describe a patient with rhabdomyolysis from the combined use of lovastatin, gemfibrozil, and clarithromycin and review the relevant literature.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Molecular Mechanisms Affecting Statin Pharmacokinetics after Bariatric Surgery.
Int J Mol Sci
September 2024
Faculty of Medicine Osijek, Josip Juraj Strossmayer University of Osijek, 31000 Osijek, Croatia.
According to recent data, one in eight people in the world struggle with obesity. Obesity management is increasingly dependent on bariatric surgical interventions, as the combination of lifestyle modifications and pharmacotherapy could have a modest long-term effect. Surgery is recommended only for individuals whose body mass index (BMI) ≥ 40 kg/m and ≥ 35 kg/m in the presence of weight-related comorbidities.
View Article and Find Full Text PDFStatins in the Cause and Prevention of Cancer: Confounding by Indication and Mediation by Rhabdomyolysis and Phosphate Toxicity.
J Cardiovasc Dev Dis
September 2024
School of Public Health Sciences, University of Waterloo, Waterloo, ON N2L 3G1, Canada.
Statins are drugs used in cardiovascular pharmacotherapy to decrease hypercholesterolemia and lower the risk of atherosclerosis. Statins also increase the risk of rhabdomyolysis, which is often minimized in comparison with large relative risk reductions of cardiovascular disease reported in clinical trials. By contrast, absolute risk reductions of cardiovascular disease are often clinically insignificant and unreported in statin clinical trials.
View Article and Find Full Text PDFAssociation Between Statin Use and Dementia, and Related Mechanisms: A Bibliometric Analysis from 2007 to 2023.
J Alzheimers Dis
September 2024
Department of Neurosurgery, The Second Affiliated Hospital of Naval Medical University, Shanghai, China.
Background: Emerging evidence suggests the potential of hydroxymethylglutaryl-coenzyme A (HMG-CoA, statins) as a therapeutic option for dementia.
Objective: The primary objective of this study is to assess the current state of research on statins use in dementia, with a focus on identifying pivotal questions within the field.
Methods: A systemic search for publications on statin use in dementia between 2007 and 2023 was conducted, utilizing the Web of Science Core Collection.
Determining the role of statins in Parkinson's disease risk reduction and disease modification: A comprehensive meta-analysis of 4 million participants' data.
CNS Neurosci Ther
August 2024
Medical research group of Egypt, Negida Academy, Arlington, Massachusetts, USA.
Background: Many observational studies have examined the association between statins and the incidence of Parkinson's disease (PD) in high-risk populations. On the other hand, clinical trials as well as other observational studies investigated the safety and efficacy of statins in slowing disease progression in PD patients. However, the evidence has been inconclusive in both questions.
View Article and Find Full Text PDFResmetirom: The First Food and Drug Administration-Approved Medication for Nonalcoholic Steatohepatitis (NASH).
Ann Pharmacother
February 2025
Lloyd L. Gregory School of Pharmacy, Palm Beach Atlantic University, West Palm Beach, FL, USA.
Article Synopsis
- Resmetirom is the first FDA-approved medication for treating nonalcoholic steatohepatitis (NASH), showing significant improvements in liver health metrics compared to placebo groups in clinical studies.
- A thorough literature search identified studies where resmetirom, dosed at 80 mg or 100 mg daily, notably improved NASH resolution and reduced liver fibrosis, highlighting its effectiveness for patients at risk of cirrhosis.
- The drug enhances treatment options for NASH patients, can be used alongside other medications, and is well tolerated, marking it as a promising choice in combination with lifestyle changes and other therapies.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!